DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Authors
Keywords
-
Journal
GUT
Volume -, Issue -, Pages gutjnl-2019-319984
Publisher
BMJ
Online
2020-08-28
DOI
10.1136/gutjnl-2019-319984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
- (2020) Johann Gout et al. GUT
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
- (2019) Piper Nicolosi et al. JAMA Oncology
- Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms
- (2019) Michael Skaro et al. GASTROENTEROLOGY
- Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
- (2019) Marinella Roberti et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy
- (2019) Qiang Zhang et al. CANCER RESEARCH
- Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
- (2019) E. Gabriela Chiorean et al. JOURNAL OF CLINICAL ONCOLOGY
- Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).
- (2019) Michael J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
- (2019) Janet E. Murphy et al. JAMA Oncology
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
- (2019) P Hammel et al. ANNALS OF ONCOLOGY
- Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
- (2019) Taiane F. Rebelatto et al. CANCER TREATMENT REVIEWS
- ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
- (2019) Samantha A. Armstrong et al. MOLECULAR CANCER THERAPEUTICS
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
- (2019) Christopher Nevala-Plagemann et al. Nature Reviews Clinical Oncology
- Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer
- (2019) Kun-I Lin et al. Cancers
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
- (2019) Max M. Wattenberg et al. BRITISH JOURNAL OF CANCER
- ATM-Mutated Pancreatic Cancer
- (2019) Candice Martino et al. PANCREAS
- Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains
- (2019) Dongju Park et al. PLoS One
- A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC)
- (2019) Sivesh K. Kamarajah et al. HPB
- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
- (2018) Eileen M. O'Reilly et al. CANCER
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
- (2018) Matthew B. Yurgelun et al. GENETICS IN MEDICINE
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable or metastatic pancreatic ductal adenocarcinoma
- (2018) Susanna Hegewisch-Becker et al. INTERNATIONAL JOURNAL OF CANCER
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
- (2018) Fatima Karzai et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
- (2018) Alex B. Blair et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
- (2018) Tomohiro Kondo et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prospective Study of Germline Genetic Testing in Incident Cases of Pancreatic Adenocarcinoma
- (2018) Randall Brand et al. CANCER
- Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
- (2018) Sebastian Mueller et al. NATURE
- Germline Variants and Risk for Pancreatic Cancer
- (2018) Wei Zhan et al. PANCREAS
- Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
- (2018) Shravanti Macherla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Importance of organoids for personalized medicine
- (2018) Lukas Perkhofer et al. Personalized Medicine
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- Targeted Therapies in Pancreatic Cancer: Promises and Failures
- (2017) Matineh Barati Bagherabad et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
- (2017) Koji Shindo et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Monogenic Diseases of DNA Repair
- (2017) Guido Keijzers et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
- (2017) Mark Yarchoan et al. Oncotarget
- Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression
- (2017) Rute M.M. Ferreira et al. Cell Reports
- ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer
- (2017) Yiannis Drosos et al. Scientific Reports
- Replication-Dependent Unhooking of DNA Interstrand Cross-Links by the NEIL3 Glycosylase
- (2016) Daniel R. Semlow et al. CELL
- DNA mismatch repair and the DNA damage response
- (2016) Zhongdao Li et al. DNA REPAIR
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Building pancreatic organoids to aid drug development
- (2016) Edgar S Wills et al. GUT
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
- (2016) Pavan P. Adiseshaiah et al. Nature Reviews Clinical Oncology
- Precision medicine in pancreatic cancer — fact or fiction?
- (2016) Thomas Seufferlein et al. Nature Reviews Gastroenterology & Hepatology
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Germline mutations in Japanese familial pancreatic cancer patients
- (2016) Erina Takai et al. Oncotarget
- Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
- (2015) David Fogelman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients
- (2015) C. Hu et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer
- (2015) Robert C. Grant et al. GASTROENTEROLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids
- (2015) Ling Huang et al. NATURE MEDICINE
- Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition
- (2015) Ronan Russell et al. Nature Communications
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
- (2015) N. J. Roberts et al. Cancer Discovery
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Organoid Cultures Derived from Patients with Advanced Prostate Cancer
- (2014) Dong Gao et al. CELL
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- BRCA1, BRCA2, PALB2 and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
- (2014) David B. Zhen et al. GENETICS IN MEDICINE
- Understanding nucleotide excision repair and its roles in cancer and ageing
- (2014) Jurgen A. Marteijn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Breast-Cancer Risk in Families with Mutations in PALB2
- (2014) Antonis C. Antoniou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hereditary breast and ovarian cancer susceptibility genes (Review)
- (2013) HIROSHI KOBAYASHI et al. ONCOLOGY REPORTS
- Repair of Strand Breaks by Homologous Recombination
- (2013) M. Jasin et al. Cold Spring Harbor Perspectives in Biology
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Inactivation of Brca2 Promotes Trp53-Associated but Inhibits KrasG12D-Dependent Pancreatic Cancer Development in Mice
- (2011) Matthew Rowley et al. GASTROENTEROLOGY
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
- (2011) M. A. Lowery et al. ONCOLOGIST
- Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
- (2010) Ferdinandos Skoulidis et al. CANCER CELL
- Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability
- (2010) A. Stolz et al. CLINICAL CANCER RESEARCH
- The MRN complex in double-strand break repair and telomere maintenance
- (2010) Brandon J. Lamarche et al. FEBS LETTERS
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic instability — an evolving hallmark of cancer
- (2010) Simona Negrini et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mre11: roles in DNA repair beyond homologous recombination
- (2009) Shan Zha et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- (2008) Cristina R. Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now